Eficacia comparativa y costo-eficacia de los nuevos anticoagulantes orales para prevención de accidente cerebrovascular en pacientes con fibrilación auricular no valvular

Wolf, 1987, Atrial fibrillation: A major contributor to stroke in the elderly: The Framingham Study, Arch Intern Med, 147, 1561, 10.1001/archinte.1987.00370090041008 Hart, 2007, Metaanalysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 Hart, 1999, Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis, Ann Intern Med, 131, 492, 10.7326/0003-4819-131-7-199910050-00003 Birman-Deych, 2006, Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation, Stroke, 37, 1070, 10.1161/01.STR.0000208294.46968.a4 Hylek, 2007, Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation, Circulation, 115, 2689, 10.1161/CIRCULATIONAHA.106.653048 Connolly, 2008, Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range, Circulation, 118, 2029, 10.1161/CIRCULATIONAHA.107.750000 Ahrens, 2010, New oral anticoagulant drugs in cardiovascular disease, Thromb Haemost, 104, 49, 10.1160/TH09-05-0327 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Ezekowitz, 2009, Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran, Am Heart J, 157, 805, 10.1016/j.ahj.2009.02.005 2010, Rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study, Am Heart J., 159, 340, 10.1016/j.ahj.2009.11.025 Lopes, 2010, Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale, Am Heart J, 159, 331, 10.1016/j.ahj.2009.07.035 Hasselblad, 2001, Statistical methods for comparison to placebo in active control trials, Drug Inf J, 35, 435, 10.1177/009286150103500212 Stangier, 2008, Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate, Clin Pharmacokinet, 47, 285, 10.2165/00003088-200847050-00001 Stangier, 2008, Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment, J Clin Pharmacol, 48, 1411, 10.1177/0091270008324179 Perzborn, 2005, In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939--an oral, direct Factor Xa inhibitor, J Thromb Haemost, 3, 514, 10.1111/j.1538-7836.2005.01166.x Kubitza, 2005, Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects, Eur J Clin Pharmacol, 61, 873, 10.1007/s00228-005-0043-5 Kubitza, 2006, Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects, J Clin Pharmacol, 46, 549, 10.1177/0091270006286904 Haas, 2009, Rivaroxaban –an oral, direct factor Xa inhibitor: lessons from a broad clinical study programme, Eur J Haematol, 82, 339, 10.1111/j.1600-0609.2009.01230.x Raghavan, 2009, Apixaban metabolism and pharmacokinetics after oral administration to humans, Drug Metab Dispos, 37, 74, 10.1124/dmd.108.023143